| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
1,4-Butanediamine-d8 dihydrochloride has no independent pharmacological target as a stable isotope internal standard. The unlabeled putrescine is an endogenous polyamine and metabolite derived from the decarboxylation of ornithine via ornithine decarboxylase (ODC). It is the precursor for the biosynthesis of higher polyamines spermidine and spermine, which are involved in cellular growth, proliferation, and differentiation. Putrescine is also an indicator of contamination caused by Cr(III) or Cr(VI) stress in higher plants.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As an internal standard, 1,4-Butanediamine-d8 dihydrochloride is not tested for in vitro pharmacological activity. In cell culture studies, it is added to cell lysates as an internal standard for the quantification of endogenous putrescine by LC-MS/MS. The deuterium label allows clear discrimination from endogenous putrescine in mass spectrometry, enabling accurate quantification of polyamine metabolism and cellular processes including cell growth, apoptosis, and stress responses. |
| ln Vivo |
1,4-Butanediamine-d8 dihydrochloride has no in vivo pharmacological activity as a therapeutic agent. It is used as an internal standard for quantifying putrescine in biological samples obtained from animal studies, including plasma, urine, and tissue homogenates. The deuterated version follows the same ADME properties as natural putrescine and is used to calibrate analytical methods without affecting physiological processes.
|
| Enzyme Assay |
For in vitro LC-MS/MS quantification, 1,4-Butanediamine-d8 dihydrochloride is dissolved in water, methanol, or 0.1% formic acid to prepare a stock solution (e.g., 1 mg/mL). The internal standard is added to biological samples (cell lysates, culture media, plasma, urine) at a fixed concentration (e.g., 10-500 ng/mL). Proteins are precipitated with methanol or acetonitrile containing 0.1% formic acid. After centrifugation (10,000-15,000 rpm, 10 minutes), the supernatant is analyzed by LC-MS/MS. The analyte-to-internal standard peak area ratio is used for quantification, correcting for matrix effects and extraction recovery. For derivatization-based methods (GC-MS), dansyl chloride or similar derivatizing agents are used.
|
| Cell Assay |
For cell-based studies, cells (e.g., cancer cell lines, neuronal cells, or hepatocytes) are cultured in standard medium (DMEM or RPMI-1640 with 10% FBS). After experimental treatments affecting polyamine metabolism (e.g., with DFMO, an ODC inhibitor), cell lysates are collected. The internal standard 1,4-Butanediamine-d8 dihydrochloride is added at a fixed concentration (e.g., 10-100 ng/mL) to the lysates. Following protein precipitation with methanol or acetonitrile and centrifugation, the supernatants are analyzed by LC-MS/MS to quantify endogenous putrescine levels. Putrescine concentrations are normalized to protein content by BCA assay.
|
| Animal Protocol |
For in vivo pharmacokinetic or metabolomic studies, 1,4-Butanediamine-d8 dihydrochloride is not administered to animals independently. It is used as an internal standard for quantifying putrescine in biological samples obtained from animals treated with experimental compounds affecting polyamine metabolism. After collection of plasma, urine, or tissue homogenates, the internal standard is added at a fixed concentration (e.g., 10-500 ng/mL). Samples are processed by protein precipitation or solid-phase extraction and analyzed by LC-MS/MS or GC-MS to determine absolute putrescine concentrations.
|
| ADME/Pharmacokinetics |
1,4-Butanediamine-d8 dihydrochloride is an internal standard and does not have independent pharmacokinetic parameters. Putrescine is an endogenous polyamine with a short half-life (minutes to hours) due to rapid metabolism by polyamine oxidases (PAO) and spermidine/spermine N1-acetyltransferase (SSAT). It is widely distributed in all tissues, with highest concentrations in the brain, prostate, and rapidly proliferating tissues. The deuterated version is used to calibrate analytical methods and does not alter the ADME properties of the endogenous analyte.
|
| Toxicity/Toxicokinetics |
1,4-Butanediamine-d8 dihydrochloride is a stable isotope-labeled internal standard with low toxicity as it is used at trace concentrations (ug-mg quantities). The unlabeled putrescine is an endogenous polyamine present in all mammalian cells at micromolar concentrations. High putrescine levels can be cytotoxic due to production of reactive oxygen species via polyamine oxidase activity. The deuterated version is chemically identical except for isotopic substitution. Standard laboratory safety precautions for handling organic compounds apply. Not intended for human consumption.
|
| References |
|
| Additional Infomation |
1,4-Butanediamine-d8 dihydrochloride is not a drug but a deuterium-labeled stable isotope internal standard. It has no approved therapeutic status, no clinical trial history, and is not intended for human consumption. This compound is used for research applications including metabolic flux analysis of polyamine biosynthesis and catabolism, as a robust internal standard for LC-MS or GC-MS quantification of putrescine in biological samples, stable isotope dilution assays for trace analyte measurement, and enzyme mechanism elucidation studies for enzymes involved in polyamine metabolism (e.g., diamine oxidases, aminotransferases). Available with ≥98% purity and 98 atom% D.
|
| Molecular Formula |
C4H6D8CL2N2
|
|---|---|
| Molecular Weight |
169.12
|
| Exact Mass |
160.053
|
| CAS # |
284665-22-1
|
| Related CAS # |
1,4-Butanediamine;110-60-1;1,4-Butanediamine dihydrochloride;333-93-7
|
| PubChem CID |
71308972
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.688
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
8
|
| Complexity |
17.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])(C([2H])([2H])C([2H])([2H])N)C([2H])([2H])N.Cl.Cl
|
| InChi Key |
XXWCODXIQWIHQN-VHGLFXLXSA-N
|
| InChi Code |
InChI=1S/C4H12N2.2ClH/c5-3-1-2-4-6;;/h1-6H2;2*1H/i1D2,2D2,3D2,4D2;;
|
| Chemical Name |
1,1,2,2,3,3,4,4-octadeuteriobutane-1,4-diamine;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9130 mL | 29.5648 mL | 59.1296 mL | |
| 5 mM | 1.1826 mL | 5.9130 mL | 11.8259 mL | |
| 10 mM | 0.5913 mL | 2.9565 mL | 5.9130 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
